YMAB Y-mAbs Therapeutics, Inc.: institutional ownership and insider trading
1 funds reported holding $881K of Y-mAbs Therapeutics, Inc. in their latest 13F filings; in Q4 2025 funds net bought $0, with 0 new positions and 1 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market; over its last four quarters it reported revenue of $85.4M and net income of −$22.2M.
YMAB revenue and earnings
- Quarter ended Jun 30, 2025: revenue $19.5M, net income −$3.24M, EPS -0.07
- Quarter ended Mar 31, 2025: revenue $20.9M, net income −$5.20M, EPS -0.12
- Quarter ended Dec 31, 2024: revenue $26.5M, net income −$6.79M, EPS -0.15
- Quarter ended Sep 30, 2024: revenue $18.5M, net income −$7.00M, EPS -0.16
Largest institutional holders of YMAB
- Nuveen Asset Management, LLC — $881K
Recent YMAB insider trades
- Mar 7, 2025: Rossi Michael J sold 3,917 shares ($20.4K)
- Mar 7, 2025: Gad Thomas sold 10,810 shares ($56.5K)
5%+ owners
- Anders Hove: 6.2% (Schedule 13G/A, filed Aug 20, 2025)
Who owns the most YMAB stock?
The largest institutional holders of Y-mAbs Therapeutics, Inc. in the latest 13F filings are Nuveen Asset Management, LLC ($881K).
Are insiders buying or selling YMAB?
No open-market insider buys or sells of Y-mAbs Therapeutics, Inc. were reported in the last 12 months.
What was YMAB's revenue last quarter?
Y-mAbs Therapeutics, Inc. reported revenue of $19.5M for the quarter ended June 30, 2025, with net income of −$3.24M.